Cardio Diagnostics Holdings, Inc. announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates for its AI-driven cardiovascular tests. The preliminary rate for Epi+Gen CHD™ is $350, and for PrecisionCHD™ is $684.76.
These preliminary payment rates are proposed as part of the calendar year 2025 gapfill pricing process and are expected to be finalized later this year. They will be effective for claims with dates of service on or after January 1, 2025.
Obtaining these specific payment rates is a significant positive development in the company’s efforts to expand timely access and improve care for Medicare patients. It provides clarity on potential reimbursement, which is crucial for commercialization and revenue generation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.